ProVise Management Group’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-21,831
| Closed | -$1.77M | – | 314 |
|
|
2023
Q4 | $1.77M | Buy |
21,831
+3,347
| +18% | +$260K | 0.15% | 134 |
|
|
2023
Q3 | $1.39M | Buy |
18,484
+13,009
| +238% | +$1M | 0.13% | 139 |
|
|
2023
Q2 | $422K | Buy |
+5,475
| New | +$437K | 0.04% | 243 |
|
|
2022
Q2 | – | Sell |
-3,405
| Closed | -$202K | – | 335 |
|
|
2022
Q1 | $202K | Sell |
3,405
-1,676
| -33% | -$107K | 0.02% | 357 |
|
|
2021
Q4 | $369K | Sell |
5,081
-210
| -4% | -$14.5K | 0.03% | 269 |
|
|
2021
Q3 | $370K | Hold |
5,291
| – | – | 0.04% | 254 |
|
|
2021
Q2 | $364K | Buy |
+5,291
| New | +$353K | 0.04% | 256 |
|
|
2021
Q1 | – | Sell |
-3,459
| Closed | -$202K | – | 355 |
|
|
2020
Q4 | $202K | Sell |
3,459
-26
| -0.7% | -$1.57K | 0.02% | 321 |
|
|
2020
Q3 | $220K | Sell |
3,485
-747
| -18% | -$51.8K | 0.03% | 261 |
|
|
2020
Q2 | $326K | Buy |
4,232
+696
| +20% | +$53.3K | 0.05% | 221 |
|
|
2020
Q1 | $264K | Sell |
3,536
-546
| -13% | -$37.7K | 0.04% | 225 |
|
|
2019
Q4 | $265K | Sell |
4,082
-1,600
| -28% | -$104K | 0.03% | 258 |
|
|
2019
Q3 | $360K | Sell |
5,682
-375
| -6% | -$24.5K | 0.05% | 227 |
|
|
2019
Q2 | $409K | Sell |
6,057
-201
| -3% | -$13.2K | 0.05% | 220 |
|
|
2019
Q1 | $407K | Sell |
6,258
-260
| -4% | -$17.3K | 0.06% | 211 |
|
|
2018
Q4 | $408K | Buy |
6,518
+317
| +5% | +$22.2K | 0.06% | 206 |
|
|
2018
Q3 | $479K | Buy |
6,201
+4
| +0.1% | +$302 | 0.06% | 220 |
|
|
2018
Q2 | $439 | Buy |
6,197
+4
| +0.1% | +$282 | 0.03% | 230 |
|
|
2018
Q1 | $467K | Sell |
6,193
-179
| -3% | -$14.2K | 0.07% | 206 |
|
|
2017
Q4 | $457K | Buy |
6,372
+104
| +2% | +$7.9K | 0.07% | 217 |
|
|
2017
Q3 | $508K | Sell |
6,268
-137
| -2% | -$10.5K | 0.07% | 208 |
|
|
2017
Q2 | $453K | Sell |
6,405
-970
| -13% | -$64.5K | 0.07% | 222 |
|
|
2017
Q1 | $501K | Buy |
7,375
+4
| +0.1% | +$281 | 0.08% | 213 |
|
|
2016
Q4 | $528K | Sell |
7,371
-792
| -10% | -$58.9K | 0.09% | 205 |
|
|
2016
Q3 | $645K | Buy |
8,163
+3,363
| +70% | +$273K | 0.11% | 184 |
|
|
2016
Q2 | $400K | Sell |
4,800
-3,008
| -39% | -$267K | 0.07% | 226 |
|
|
2016
Q1 | $717K | Sell |
7,808
-597
| -7% | -$53.8K | 0.15% | 153 |
|
|
2015
Q4 | $851K | Buy |
8,405
+460
| +6% | +$47.9K | 0.18% | 133 |
|
|
2015
Q3 | $780K | Buy |
7,945
+1,150
| +17% | +$128K | 0.18% | 137 |
|
|
2015
Q2 | $796K | Sell |
6,795
-400
| -6% | -$43.7K | 0.17% | 140 |
|
|
2015
Q1 | $706K | Buy |
7,195
+600
| +9% | +$60.9K | 0.15% | 149 |
|
|
2014
Q4 | $622K | Sell |
6,595
-4,705
| -42% | -$487K | 0.13% | 161 |
|
|
2014
Q3 | $1.2M | Buy |
11,300
+1,800
| +19% | +$176K | 0.26% | 116 |
|
|
2014
Q2 | $788K | Hold |
9,500
| – | – | 0.17% | 154 |
|
|
2014
Q1 | $673K | Buy |
9,500
+1,650
| +21% | +$129K | 0.16% | 155 |
|
|
2013
Q4 | $590K | Buy |
7,850
+3,050
| +64% | +$212K | 0.15% | 162 |
|
|
2013
Q3 | $302K | Hold |
4,800
| – | – | 0.09% | 236 |
|
|
2013
Q2 | $246K | Buy |
+4,800
| New | +$250K | 0.07% | 267 |
|
Other funds holding GILD
ProVise Management Group's GILD Position: Q1 2024 in Review
ProVise Management Group sold out of Gilead Sciences (GILD) in Q1 2024, closing a stake of 21,831 shares — an estimated $1.77M sold.
ProVise Management Group first reported a position in GILD in Q2 2013 and held it in 38 quarters. The position peaked at $1.77M in Q4 2023. 1,721 funds tracked by Wall St. Rank hold GILD as of Q1 2024.
- ProVise Management Group reported no remaining Gilead Sciences position as of Q1 2024 after selling out during the quarter.
- ProVise Management Group sold 21,831 Gilead Sciences shares in Q1 2024, an estimated $1.77M.
- ProVise Management Group first reported a position in Gilead Sciences in Q2 2013 and held it in 38 quarters.
- ProVise Management Group's Gilead Sciences position peaked at $1.77M in Q4 2023.
- 1,721 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2024.
Based on ProVise Management Group's 13F filing for Q1 2024, filed 9 May 2024.